ImmuCell Corporation (ICCC): Price and Financial Metrics

ImmuCell Corporation (ICCC): $10.95

-0.48 (-4.20%)

POWR Rating

Component Grades













Add ICCC to Watchlist
Sign Up

Industry: Biotech


of 481

in industry

ICCC Stock Summary

  • ICCC has a higher market value than only 13.14% of US stocks; more precisely, its current market capitalization is $78,981,463.
  • ICCC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 228.99 -- higher than 84.83% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Immucell Corp is higher than 92.96% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Immucell Corp are OIIM, MOSY, KMDA, SLRX, and INTZ.
  • ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to

ICCC Stock Price Chart Interactive Chart >

Price chart for ICCC

ICCC Price/Volume Stats

Current price $10.95 52-week high $13.20
Prev. close $11.43 52-week low $3.70
Day low $10.88 Volume 21,700
Day high $11.49 Avg. volume 69,285
50-day MA $8.45 Dividend yield N/A
200-day MA $6.14 Market Cap 78.98M

ImmuCell Corporation (ICCC) Company Bio

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.

ICCC Latest News Stream

Event/Time News Detail
Loading, please wait...

ICCC Latest Social Stream

Loading social stream, please wait...

View Full ICCC Social Stream

Latest ICCC News From Around the Web

Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2020 Results - Earnings Call Transcript

ImmuCell Corporation (ICCC) Q4 2020 Earnings Conference Call February 23, 2021 09:00 A.M. ET Company Participants Joe Diaz - Lytham Partners Michael F. Brigham - President and CEO Conference Call Participants Sam Rebotsky - SER Asset Management George Melas-Kyriazi - MKH Management Unidentified Analyst - Private Investor Louis Parks -...

SA Transcripts on Seeking Alpha | February 23, 2021

ImmuCell Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 23, 2021 / ImmuCell Corp. (NASDAQ:ICCC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 9:00 AM Eastern Time.

Yahoo | February 23, 2021

ImmuCell EPS beats by $0.10, beats on revenue

ImmuCell (ICCC): FY GAAP EPS of -$0.14 beats by $0.10.Revenue of $15.3M beats by $0.16M.Press Release...

Seeking Alpha | February 22, 2021

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020

Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2020 after the market closes on Monday, February 22, 2021. The Company has scheduled a conference call the next morning, Tuesday, February 23, 2021, at 9:00 AM ET to review the results. Interested parties can access the conference call scheduled by the Company to review the full year 2020 financial results by dialing (844) 855-9502 (toll free) or (412...

Yahoo | February 16, 2021

The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) I...

Benzinga | January 28, 2021

Read More 'ICCC' Stories Here

ICCC Price Returns

1-mo 9.94%
3-mo 89.82%
6-mo 105.97%
1-year 115.13%
3-year 50.00%
5-year 76.90%
YTD 84.03%
2020 15.53%
2019 -26.95%
2018 -19.80%
2017 47.73%
2016 N/A

Continue Researching ICCC

Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:

Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8283 seconds.